Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC.

Balko JM, Jones BR, Coakley VL, Black EP.

Cancer Biol Ther. 2009 Mar 15;8(6):522-30. doi: 10.4161/cbt.8.6.7690. Epub 2009 Mar 15.

PMID:
19305165
2.

Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.

Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M.

Cancer Sci. 2009 Aug;100(8):1526-31. doi: 10.1111/j.1349-7006.2009.01197.x. Epub 2009 May 13.

4.
5.
7.

Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.

Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS.

Lung Cancer. 2007 Apr;56(1):25-33. Epub 2006 Dec 15.

PMID:
17175059
8.

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.

J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3.

9.

Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.

Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, Merkelbach-Bruse S, Buettner R, Heukamp LC.

J Cancer Res Clin Oncol. 2009 May;135(5):723-30. doi: 10.1007/s00432-008-0509-9. Epub 2008 Nov 11.

PMID:
19002495
10.

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Jänne PA.

Cancer Discov. 2015 Sep;5(9):960-971. doi: 10.1158/2159-8290.CD-15-0063. Epub 2015 Jun 2.

11.

Combination of EGFR signalling pathway inhibitors and prevention of resistance.

Cornelissen B.

Cancer Biol Ther. 2009 Mar 15;8(6):531-2. doi: 10.4161/cbt.8.6.7893. Epub 2009 Mar 15. No abstract available.

PMID:
19242100
12.

Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.

Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK, Kufe D.

Clin Cancer Res. 2014 Nov 1;20(21):5423-34. doi: 10.1158/1078-0432.CCR-13-3168. Epub 2014 Sep 4.

14.

Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis.

Zhang X, Li Y, Li H, Qin Y, Bai C, Xu F, Zhu T, Xu J, Wu M, Wang C, Wei L, He J.

PLoS One. 2012;7(8):e40178. doi: 10.1371/journal.pone.0040178. Epub 2012 Aug 16. Review.

15.

Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway.

Li C, Fan S, Owonikoko TK, Khuri FR, Sun SY, Li R.

Oncogene. 2011 Sep 1;30(35):3802-12. doi: 10.1038/onc.2011.94. Epub 2011 Apr 11.

16.

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.

Yoon YK, Kim HP, Han SW, Oh DY, Im SA, Bang YJ, Kim TY.

Mol Carcinog. 2010 Apr;49(4):353-62. doi: 10.1002/mc.20607.

PMID:
20358631
17.

Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.

Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, Shokat KM, Nicolaides T, Weiss WA.

Cancer Discov. 2012 May;2(5):450-7. doi: 10.1158/2159-8290.CD-11-0287. Epub 2012 Mar 31.

18.

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.

Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D'Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L, Ciardiello F.

Br J Cancer. 2012 May 8;106(10):1648-59. doi: 10.1038/bjc.2012.129.

19.

Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells.

Umelo IA, Wever OD, Kronenberger P, Noor A, Teugels E, Chen G, Bracke M, Grève JD.

Lung Cancer. 2015 Nov;90(2):167-74. doi: 10.1016/j.lungcan.2015.08.008. Epub 2015 Aug 20.

20.

MEK inhibition in non-small cell lung cancer.

Stinchcombe TE, Johnson GL.

Lung Cancer. 2014 Nov;86(2):121-5. doi: 10.1016/j.lungcan.2014.09.005. Epub 2014 Sep 16. Review.

Supplemental Content

Support Center